A potent PI3Kδ inhibitor for CLL is idelalisib, which blocks the constitutive activation of the p110δ-dependent PI3K pathway, decreasing p-Akt, induces apoptosis by caspase activation, and inhibits stroma–CLL cell contacts, resulting in relevant anticancer activity [61]. The gene discussed is AKT1; the disease is B-cell chronic lymphocytic leukemia.